5-Aminolevulinic acid HClCAS# 5451-09-2 |
- Verteporfin
Catalog No.:BCC3690
CAS No.:129497-78-5
- Miglustat hydrochloride
Catalog No.:BCC5186
CAS No.:210110-90-0
- Hydrochlorothiazide
Catalog No.:BCC4786
CAS No.:58-93-5
- Miglustat
Catalog No.:BCC5187
CAS No.:72599-27-0
- TPT-260
Catalog No.:BCC5171
CAS No.:769856-81-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 5451-09-2 | SDF | Download SDF |
PubChem ID | 123608 | Appearance | Powder |
Formula | C5H10ClNO3 | M.Wt | 167.59 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | ALA; 5-ALA | ||
Solubility | DMSO : ≥ 150 mg/mL (895.04 mM) H2O : ≥ 50 mg/mL (298.35 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | 5-amino-4-oxopentanoic acid;hydrochloride | ||
SMILES | [H+].[Cl-].NCC(=O)CCC(O)=O | ||
Standard InChIKey | ZLHFONARZHCSET-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C5H9NO3.ClH/c6-3-4(7)1-2-5(8)9;/h1-3,6H2,(H,8,9);1H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Substrate for detection of δ-aminolevulinic acid dehydratase. Used in fluorescence guided resection of tumors. |
5-Aminolevulinic acid HCl Dilution Calculator
5-Aminolevulinic acid HCl Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 5.9669 mL | 29.8347 mL | 59.6694 mL | 119.3389 mL | 149.1736 mL |
5 mM | 1.1934 mL | 5.9669 mL | 11.9339 mL | 23.8678 mL | 29.8347 mL |
10 mM | 0.5967 mL | 2.9835 mL | 5.9669 mL | 11.9339 mL | 14.9174 mL |
50 mM | 0.1193 mL | 0.5967 mL | 1.1934 mL | 2.3868 mL | 2.9835 mL |
100 mM | 0.0597 mL | 0.2983 mL | 0.5967 mL | 1.1934 mL | 1.4917 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
5-Aminolevulinic acid HCl is an intermediate in heme biosynthesis in the body and the universal precursor of tetrapyrroles.
- Erythrodiol
Catalog No.:BCN5726
CAS No.:545-48-2
- Lupeol
Catalog No.:BCN5725
CAS No.:545-47-1
- Uvaol
Catalog No.:BCN5724
CAS No.:545-46-0
- 5-Glutinen-3-ol
Catalog No.:BCN5723
CAS No.:545-24-4
- Jolkinolide E
Catalog No.:BCN3772
CAS No.:54494-34-7
- 3alpha-dihydrocadambine
Catalog No.:BCN8151
CAS No.:54483-84-0
- JNJ 10181457 dihydrochloride
Catalog No.:BCC7842
CAS No.:544707-20-2
- UBP 282
Catalog No.:BCC7171
CAS No.:544697-47-4
- MRS 1845
Catalog No.:BCC7198
CAS No.:544478-19-5
- c-di-AMP
Catalog No.:BCC8054
CAS No.:54447-84-6
- HIV-1 integrase inhibitor
Catalog No.:BCC1618
CAS No.:544467-07-4
- Capadenoson
Catalog No.:BCC1450
CAS No.:544417-40-5
- H-Leu-CMK.HCl
Catalog No.:BCC2971
CAS No.:54518-92-2
- Methyl protodioscin
Catalog No.:BCN6342
CAS No.:54522-52-0
- Methyl protogracillin
Catalog No.:BCN8177
CAS No.:54522-53-1
- Nicardipine HCl
Catalog No.:BCC4685
CAS No.:54527-84-3
- QNZ (EVP4593)
Catalog No.:BCC2249
CAS No.:545380-34-5
- AMG 9810
Catalog No.:BCC7329
CAS No.:545395-94-6
- Quercetin-3-O-glucose-6'-acetate
Catalog No.:BCN6545
CAS No.:54542-51-7
- Doxercalciferol
Catalog No.:BCC4902
CAS No.:54573-75-0
- Conessine
Catalog No.:BCC7352
CAS No.:546-06-5
- Alantolactone
Catalog No.:BCN1033
CAS No.:546-43-0
- α-Thujone
Catalog No.:BCC8271
CAS No.:546-80-5
- Columbin
Catalog No.:BCN2622
CAS No.:546-97-4
A HCl/alcohol formulation increased 5-aminolevulinic acid skin distribution using an ex vivo full thickness porcine skin model.[Pubmed:18380780]
Exp Dermatol. 2008 Oct;17(10):813-20.
Topical photodynamic therapy with 5-aminolevulinic acid (5-ALA) is a newly established treatment modality for epithelial skin cancer. Skin distribution of different 20% 5-ALA formulations was investigated by detection of protoporphyrin IX (PpIX) using an ex vivo porcine skin model. Fluorescence of PpIX was first detectable at 2 h after application of a 5-ALA/HCl-alcohol solution, followed by a 5-ALA gel +/- 40% DMSO > 5-ALA lipophilic ointment > 5-ALA hydrophilic ointment at 4 h after application. Intensity of PpIX was 10-fold higher after 5-ALA/HCl-alcohol application in contrast to 5-ALA hydrophilic ointment. Maxima of PpIX fluorescence were measured between 18 and 24 h after application. PpIX accumulation induced by 5-ALA within the lower parts of the epidermis was increased in order of 5-ALA hydrophilic ointment < 5-ALA lipophilic ointment < 5-ALA gel w/o DMSO < 5-ALA gel with DMSO < 5-ALA/HCl-alcohol. Illumination of skin incubated with different 5-ALA formulations led to a marked increase of apoptotic cells in the epidermis depending on the penetration depth of the 5-ALA formulations. A formulation containing short chain alcohols have been observed to increase the permeation and distribution of 5-ALA. PpIX fluorescence was detected earlier yielding to photodynamic effective amounts of PpIX in the epidermis as compared with all other 5-ALA formulations used. These data emphasizes the potential of investigating properties of new formulations using such a full thickness porcine skin model.
Clinical utility of 5-aminolevulinic acid HCl to better visualize and more completely remove gliomas.[Pubmed:27672334]
Onco Targets Ther. 2016 Sep 12;9:5629-42.
Surgical resection is typically the first line of treatment for gliomas. However, the neurosurgeon faces a major challenge in achieving maximal resection in high-grade gliomas as these infiltrative tumors make it difficult to discern tumor margins from normal brain with conventional white-light microscopy alone. To aid in resection of these infiltrative tumors, fluorescence-guided surgery has gained much popularity in intraoperative visualization of malignant gliomas, with 5-aminolevulinic acid (5-ALA) leading the way. First introduced in an article in Neurosurgery, 5-ALA has since become a safe, effective, and inexpensive method to visualize and improve resection of gliomas. This has undoubtedly led to improvements in the clinical course of patients as demonstrated by the increased overall and progression-free survival in patients with such devastating disease. This literature review aims to discuss the major studies and trials demonstrating the clinical utility of 5-ALA and its ability to aid in complete resection of malignant gliomas.